Bsenexus Terminal Open in Bsenexus App →
OTHER BSE: 532321

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".

Filing Details / Description
Press Release - Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".
🔗 Related Announcements 5 Disclosures
Anzen India Energy Yield Plus Trust OTHER
Anzen India Energy Yield Plus Trust - 543655 - Reg 26K: Quarterly Compliance Report on Corporate governance
Bluspring Enterprises Ltd OTHER
Bluspring Enterprises Ltd - 544414 - Reply To The ''''Clarification Sought On Volume Movement Letter''''
Paisalo Digital Ltd OTHER
Paisalo Digital Ltd - 532900 - Announcement under Regulation 30 (LODR)-Meeting Updates
Mahaveer Infoway Ltd OTHER
Mahaveer Infoway Ltd - 539383 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Bandhan Bank Ltd OTHER
Bandhan Bank Ltd - 541153 - Rumour verification - Regulation 30(11)
📄 View Official BSE Filing (PDF) ↗ Explore Live BSE Corporate Disclosures on Bsenexus →